Corporate Clients

Realise potential, meet goals, and build value.

Results works as a trusted adviser to corporate clients, including some of the world’s leading pharmaceutical companies. Our clients know they can count on our track-record, depth of experience, professionalism and exceptional technical capabilities.

We work closely with corporate clients that need sector specialist advisors for their buy-side or sell-side M&A needs. Our solutions include strategic reviews of business or facility portfolios, support for acquisitions and divestments, as well as advising on licensing transactions for marketed products.

Commitment to client service is a hallmark of our project teams.

Our disciplined approach and strong technical capability allow our corporate clients to execute projects with confidence and achieve their strategic goals.

We pride ourselves on our integrity and straight talking, giving the best advice to our clients. We are focused on getting the best outcome: we think this demands an adviser who will be clear and considered however complex or pressurised the situation.

David Sanders

Managing Director

Services

We’ve been providing independent M&A and corporate finance advice and execution services to entrepreneurs, corporates and investors in the technology and healthcare sectors for over 30 years. Whether your aim is to realise value or to find a partner for future growth, we will be your guide.

M&A

When the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business.

Divestments

With a strong track record in company carve-outs, we can help you realign your portfolio and redeploy capital to the growth of your core business.

Licensing

We support clients with in-licensing, out-licensing, drug licensing, and facility licensing and we understand the complexities that are unique to licensing deals.

Equity Fundraising

We understand that optimising terms is critical, but so is finding the right partner for growth. We help articulate your equity story, target the best investors and negotiate the right deal.

Strategic Advice

Having completed over 300 transactions, we bring the breadth of perspectives and depth of business experience to provide advice on strategic options for businesses.

Recent Deals

Jul 2022
has received investment from
Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
Has invested in
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Apr 2022
has received investment from
and EnBW New Ventures, with follow-on investment from ETF Partners
Apr 2022
has been acquired by
A company backed by TA Associates, HGGC, Charlesbank, Harvest Partners SCF
Apr 2022
has been acquired by
Mar 2022
An AlbionVC-backed company
has received investment from
Morgan Stanley Expansion Capital and Keyhaven Capital Partners co-invest

Results. Great people creating great outcomes, together.

Latest Insights

Corporate News
3rd August 2022

We are joining forces with Canaccord Genuity

We are very excited to share that we have agreed to join forces with Canaccord Genuity – a leading full-service investment bank serving growth companies in the middle market.  This is an important milestone in our journey and we wanted to update you on why we’ve taken this decision and what it means for you. […]

Insights
27th July 2022

Transforming healthcare with real-world evidence (RWE)

The healthcare industry experienced a revolutionary shift when it switched from practising medicine as an art to evidence-based medicine, which is based on relatively simple randomised clinical trials to determine which treatment option was safe and effective. Through the years, evidence-based medicine became the gold standard for clinical development. However, this method has become less […]

Reports
19th July 2022

The Technology Services Perspective – Q2 2022

H1 2022 deal volumes have increased significantly across the board, up 37% over H1 2021. Strategic M&A continues to drive this quarter’s deal activity, namely acquiring footholds in near/offshore hotspots, vendor-specific tech stacks (particularly AWS, Salesforce and SAP) and or next-gen capabilities, such as conversational AI and data analytics. Public tech companies broadly tracked the […]